Actinium Highlights Mutation Data From The Phase 3 SIERRA Trial Of Iomab-B And Novel Linker Technology To Support Solid Tumor Antibody Radiation Conjugate Development At The 2024 SNMMI Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals presented promising data from the Phase 3 SIERRA trial of Iomab-B at the 2024 SNMMI Annual Meeting. Iomab-B showed improved survival in high-risk relapsed or refractory acute myeloid leukemia patients and achieved the primary endpoint of durable Complete Remission with high statistical significance. Additionally, Actinium's novel linker technology demonstrated high tumor uptake and in vivo stability in preclinical models.
June 10, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actinium Pharmaceuticals' Iomab-B achieved the primary endpoint of durable Complete Remission in the Phase 3 SIERRA trial, showing significant potential for improving survival in high-risk AML patients. The company's novel linker technology also demonstrated promising preclinical results.
The successful achievement of the primary endpoint in a Phase 3 trial is a significant milestone for Actinium Pharmaceuticals. This result, combined with the promising preclinical data on their novel linker technology, is likely to positively impact the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100